Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1) - Poll - MDSpire

Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1)

  • By

  • Yoshio Nakamura

  • Naoya Yamazaki

  • Kenjiro Namikawa

  • Hiroshi Uchi

  • Shoichiro Mori

  • Mariko Ogawa-Momohara

  • Taku Fujimura

  • Tatsuya Takenouchi

  • Mana Kurimoto

  • Yuki Yamamoto

  • Atsushi Otsuka

  • Kenji Kabashima

  • Takayuki Fusumae

  • Ikuko Hirai

  • Keiji Tanese

  • Yasuko Saito

  • Masayuki Amagai

  • Ryo Takemura

  • Yasunori Sato

  • Takeru Funakoshi

  • March 4, 2026

  • 0 min

Share

Original Source(s)

Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1)

  • by Yoshio Nakamura, Naoya Yamazaki, Kenjiro Namikawa, Hiroshi Uchi, Shoichiro Mori, Mariko Ogawa-Momohara, Taku Fujimura, Tatsuya Takenouchi, Mana Kurimoto, Yuki Yamamoto, Atsushi Otsuka, Kenji Kabashima, Takayuki Fusumae, Ikuko Hirai, Keiji Tanese, Yasuko Saito, Masayuki Amagai, Ryo Takemura, Yasunori Sato, Takeru Funakoshi

  • March 4, 2026

Related Content

Genetic Variants Linked to Multiple Non-melanoma Skin Cancers: A Study of 19 SNPs in an Italian Population

A Novel Framework for Skin Lesion Classification Using Hierarchical Attention Stacked Ensemble and Matthews Correlation Coefficient Weighted Averaging

Obesity’s Cancer Role Underestimated

A proposed framework highlights potential sources of bias in current estimates